Luxsol Suspension Solution
What is Luxsol® Suspension Solution? Luxsol Suspension Solution is a targeted therapeutic therapy treatment for Respiratory illness associated with Covid-19 and influenza. It is not a pill or an injection. It is a spray through the mouth and directly to lungs using a nebulizer.
None. No known side effects.
History of Luxsol suspension solution
- May 22nd, 2020 Prioritized Examination Pilot Program started. Luxsol Suspension Solution Patent Application was submitted
- June 4th, 2020 Granted Prioritized Examination Status as part of USPTO to treat Covid-19 and Influenza.
- January 7th, 2021 3V Medical Research Group was notified of the approval of the application to treat Covid-19 and Influenza (Patent approved within 7 months)
Luxsol Suspension Solution was successfully tested in treatment of Covid-19 in a In Vitro Study using Remdesivir as the positive Control. Results were equally effective to kill the SARS-COV-2 as Remdesivir.
In Vitro Study SOW (click here)
Final In Vitro Study test report (click here)
In Vivo Study, Safety/Toxicity results (click here)
Luxsol Suspension Solution is one of the treatments in the USA to receive USPTO granted to treat Covid-19 virus and Influenza.
3V Medical Research Group developed Luxsol® Suspension Solution as a targeted therapeutic therapy to treat Covid-19.